{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:46:44Z","timestamp":1790275604010,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1097\/cmr.0b013e32832a1e2f","type":"journal-article","created":{"date-parts":[[2009,7,16]],"date-time":"2009-07-16T03:28:46Z","timestamp":1247714926000},"page":"238-242","source":"Crossref","is-referenced-by-count":21,"title":["Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients"],"prefix":"10.1097","volume":"19","author":[{"given":"Jade","family":"Homsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agop Y.","family":"Bedikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jen","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy L.","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R2-7-20210129","first-page":"2351","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.","volume":"18","author":"Middleton","year":"2000","journal-title":"Erratum in: J Clin Oncol"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2002.20.1.125","article-title":"Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma","volume":"20","author":"Agarwala","year":"2002","journal-title":"J Clin Oncol"},{"key":"R4-7-20210129","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J Clin Oncol"},{"key":"R5-7-20210129","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"R6-7-20210129","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00194546","article-title":"A phase II study of taxol in patients with malignant melanoma","volume":"9","author":"Einzig","year":"1991","journal-title":"Invest New Drugs"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.1995.13.12.2895","article-title":"Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy","volume":"13","author":"Bedikian","year":"1995","journal-title":"J Clin Oncol"},{"key":"R8-7-20210129","first-page":"3229","article-title":"Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel","volume":"7","author":"Bradley","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-3659(01)00321-2","article-title":"Tumor targeting by conjugation of DHA to paclitaxel","volume":"74","author":"Bradley","year":"2001","journal-title":"J Control Release"},{"key":"R10-7-20210129","first-page":"3589","article-title":"Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile","volume":"9","author":"Wolff","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","article-title":"Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks","volume":"23","author":"Green","year":"2005","journal-title":"J Clin Oncol"},{"key":"R13-7-20210129","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"R15-7-20210129","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1021\/ja00738a045","article-title":"Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia","volume":"93","author":"Wani","year":"1971","journal-title":"J Am Chem Soc"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"R17-7-20210129","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.1987.5.8.1232","article-title":"Phase I trial of taxol given as a 24-h infusion every 21 days: responses observed in metastatic melanoma","volume":"5","author":"Wiernik","year":"1987","journal-title":"J Clin Oncol"},{"key":"R18-7-20210129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00000421-200206000-00016","article-title":"Phase II study of paclitaxel and carboplatin for malignant melanoma","volume":"25","author":"Hodi","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"R20-7-20210129","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00008390-200402000-00010","article-title":"Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma","volume":"14","author":"Bedikian","year":"2004","journal-title":"Melanoma Res"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00008390-200310000-00012","article-title":"Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG)","volume":"13","author":"Zimpfer-Rechner","year":"2003","journal-title":"Melanoma Res"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S","article-title":"A phase II trial of taxol in metastatic melanoma","volume":"65","author":"Legha","year":"1990","journal-title":"Cancer"},{"key":"R23-7-20210129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00008390-200510000-00015","article-title":"Phase II trial of weekly paclitaxel in patients with advanced melanoma","volume":"15","author":"Walker","year":"2005","journal-title":"Melanoma Res"},{"key":"R24-7-20210129","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1081\/CNV-120001181","article-title":"Phase II trial of paclitaxel and dacarbazine with filgrastim administration in advanced malignant melanoma","volume":"20","author":"Feun","year":"2002","journal-title":"Cancer Invest"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000138351","article-title":"Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma","volume":"74","author":"Gonz\u00e1lez-Cao","year":"2008","journal-title":"Oncology"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.1999.17.11.3403","article-title":"Randomized trial of 3-h versus 24-h infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26","volume":"17","author":"Smith","year":"1999","journal-title":"J Clin Oncol"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1997.15.1.187","article-title":"Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer","volume":"15","author":"Fennelly","year":"1997","journal-title":"J Clin Oncol"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00280-007-0486-8","article-title":"A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma","volume":"61","author":"Jones","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R29-7-20210129","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/01243894-200611000-00011","article-title":"DHA-paclitaxel (taxoprexin) as first-line treatment in patients with stage IIIB or IV non-small cell lung cancer: report of a phase II open-label multicenter trial","volume":"1","author":"Payne","year":"2006","journal-title":"J Thorac Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00008390-200908000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:55:18Z","timestamp":1786038918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008390-200908000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0b013e32832a1e2f","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}